Tag American Society of Hematology

The Phase 3 trial investigating Sarclisa® in combination with carfilzomib, lenalidomide and dexamethasone showed a statistically significant improvement in the rate of minimal residual disease negativity, compared with KRd alone.

The Phase 3 trial investigating Sarclisa® (isatuximab) in combination with carfilzomib, lenalidomide and dexamethasone (KRd) showed a statistically significant improvement in the rate of minimal residual disease (MRD) negativity, compared with KRd alone, after autologous stem cell transplant (ASCT) consolidation…

Results from the VALENTINE-PTCL01 Phase 2 trial of EZHARMIA® showed clinically meaningful and durable responses in patients with relapsed or refractory peripheral T-cell lymphoma.

Results from the VALENTINE-PTCL01 phase 2 trial of Daiichi Sankyo’s EZHARMIA® (valemetostat tosilate) showed clinically meaningful and durable responses in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The data were presented in an oral session at the 2023…

The primary analysis of the Phase 3 HAVEN 7 study reinforced the efficacy and safety of Hemlibra® in previously untreated or minimally treated infants with severe haemophilia A without Factor VIII inhibitors.

Roche announced that the primary analysis of the Phase III HAVEN 7 study reinforced the efficacy and safety of Hemlibra® (emicizumab) in previously untreated or minimally treated infants with severe haemophilia A without factor VIII inhibitors. Results showed that Hemlibra…

New data from the ongoing Phase 1/2 EPCORE™ NHL-1 clinical trial investigating epcoritamab demonstrated an ORR of 82 percent, a CR rate of 63 percent and MRD negativity rate of 67 percent in patients with R/R follicular lymphoma.

Genmab and AbbVie announced new data from the ongoing phase 1/2 EPCORE™ NHL-1 clinical trial investigating epcoritamab (DuoBody® CD3xCD20), a T-cell engaging bispecific antibody administered subcutaneously, demonstrated an overall response rate (ORR) of 82 percent, a complete response (CR) rate…